A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer

Journal of Pediatric Hematology/Oncology

Volumn 27, Issue 11, 2005, Pages 573-581

  Kieran, Mark W ^a,b   Turner, Christopher D ^a,b   Rubin, Joshua B ^c   Chi, Susan N ^a,b   Zimmerman, Mary Ann ^a,b   Chordas, Christine ^a,b   Klement, Giannoula ^a,b   Laforme, Andrea ^a,b   Gordon, Amanda ^a   Thomas, Amanda ^a   Neuberg, Donna ^a   Browder, Timothy ^b   Folkman, Judah ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c ST LOUIS CHILDREN S HOSPITAL   (United States)

Author keywords

Angiogenesis; Antiangiogenesis; Clinical trial; Metronomic; Pediatric; Therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; BASIC FIBROBLAST GROWTH FACTOR; CELECOXIB; CYCLOPHOSPHAMIDE; ENDOSTATIN; ETOPOSIDE; THALIDOMIDE; THROMBOSPONDIN; THROMBOSPONDIN 1; VASCULOTROPIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMENORRHEA; ANTIANGIOGENIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE ACTIVITY; DISEASE MARKER; DOSE RESPONSE; DRUG TOLERABILITY; FEASIBILITY STUDY; HUMAN; HYPOKALEMIA; INFANT; INFECTION; LYMPHOCYTOPENIA; NEUTROPENIA; NEWBORN; PRIORITY JOURNAL; RADIOGRAPHY; RECURRENT CANCER; SEDATION; SEIZURE; SIDE EFFECT; SYNCOPE; TOXICITY; TREATMENT OUTCOME; TREATMENT REFUSAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; ENDOSTATINS; FEASIBILITY STUDIES; FIBROBLAST GROWTH FACTOR 2; HUMANS; INFANT; MAXIMUM TOLERATED DOSE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; THROMBOSPONDINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 28144453993     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/01.mph.0000183863.10792.d4     Document Type: Article

References (40)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
2. Drevs J, Laus C, Mendinger M, et al. Antiangiogenesis: current clinical data and future perspectives. Onkologie. 2002;25:520-527.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
4. Browder T, Butterfield CE, Kräling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878-1886.
5. Hahnfeldt P, Folkman J, Hlatky L. Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol. 2003;220:545-554.
6. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor- 2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000;105:R15-R24.
7. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105:1045-1047.
8. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective anti-angiogenic window for various chemotherapeutic drugs. Cancer Res. 2002;62:6938-6943.
9. Bocci G, Francia G, Man S, et al. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA. 2003;100:12917-12922.
10. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423-436.
11. Chan LW, Moses MA, Goley E, et al. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol. 2004;22:499-506.
12. Fulton D, Urtasun R, Forsyth P. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J Neurooncol. 1996;27:149-155.
13. Ashley DM, Meier L, Kerby T, et al. Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol. 1996;14:1922-1927.
14. Kushner BH, Kramer K, Cheung NK. Oral etoposide for refractory and relapsed neuroblastoma. J Clin Oncol. 1999;17:3221-3225.
15. Asou N, Suzushima H, Nishimura S, et al. Long-term remission in an elderly patient with mantle cell leukemia treated with low-dose cyclophosphamide. Am J Hematol. 2000;63:35-37.
16. Nicolini A, Mancini P, Ferrari P, et al. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomed Pharmacother. 2004;58:447-450.
17. Chantarawiroj P, Tresukosol D, Kudelka AP, et al. Prolonged oral etoposide for refractory advanced uterine leiomyosarcoma. Gynecol Oncol. 1995;58:248-250.
18. Aguayo A, Giles F, Albitar M. Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic syndromes. Leuk Lymphoma. 2003;44:213-222.
19. Kieran MW, Billett A. Antiangiogenesis therapy. Current and future agents. Hematol Oncol Clin North Am. 2001;15:835-851.
20. Schuetz E, Lan L, Yasuda K, et al. Development of a real-time in vivo transcription assay: application reveals pregnane X receptor-mediated induction of CYP3A4 by cancer chemotherapeutic agents. Mol Pharmacol. 2002;62:439-445.
21. Baldwin A, Huang Z, Jounaidi Y, et al. Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer. Arch Biochem Biophys. 2003;409:197-206.
22. Chang TK, Waxman DJ. Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard. Cancer Res. 1993;53:2490-2497.
23. Marx GM, Pavlakis N, McCowatt S, et al. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J Neurooncol. 2001;54:31-38.
24. Juliusson G, Celsing F, Turesson I, et al. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol. 2000;109:89-96.
25. Phillips RK, Wallace MH, Lynch PM, et al. A randomised, double-blind, placebo-controlled study of celecoxib, a selective cyclooxygenase-2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut. 2002;50:857-860.
26. Evans SR, Krown SE, Testa MA, et al. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study. J Clin Oncol. 2002;20:3236-3241.
27. Chamberlain MC. Recurrent intracranial ependymoma in children: salvage therapy with oral etoposide. Pediatr Neurol. 2001;24:117-121.
28. Ajani JA, Mansfield PF, Dumas P. Oral etoposide for patients with metastatic gastric adenocarcinoma. Cancer J Sci Am. 1999;5:112-114.
29. Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002;13:73-80.
30. Leahy KM, Ornberg RL, Wang Y, et al. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 2002;62:625-631.
31. Man S, Bocci G, Francia G, et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 2002;62:2731-2735.
32. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082-4085.
33. Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol. 1998;55:1827-1834.
34. Klein SA, Bond SJ, Gupta SC, et al. Angiogenesis inhibitor TNP-470 inhibits murine cutaneous wound healing. J Surg Res. 1999;82:268-274.
35. Hazzard TM, Rohan RM, Molskness TA, et al. Injection of antiangiogenic agents into the macaque preovulatory follicle: disruption of corpus luteum development and function. Endocrine. 2002;17:199-206.
36. Folkman J, Kalluri R. Tumor angiogenesis. In Kufe DW, Pollock RE, Weischelbaum RR, et al., eds. Cancer Medicine. Hamilton, Ontario: BC Decker, 2003:161-194.
37. Lawler J, Detmar M. Tumor progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol. 2004;36:1038-1045.
38. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, et al. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA. 2001;98:12485-12490.
39. Nieder C, Andratschke N, Jeremic B, et al. Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer. Anticancer Res. 2003;23:5117-5123.
40. Brattstrom D, Bergqvist M, Hesselius P, et al. Serum VEGF and bFGF adds prognostic information in patients with normal platelet counts when sampled before, during and after treatment for locally advanced non-small cell lung cancer. Lung Cancer. 2004;43:55-62.